NASDAQ · ABVX
Abivax SA financials
$98.50+1.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q4 '25 Dec 31 | Q4 '24 Dec 31 | Q4 '23 Dec 31 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Gross margin | — | — | — |
| Operating income | — | — | — |
| Net income | — | — | — |
| Net margin | — | — | — |
| Diluted EPS | — | — | — |
| EBITDA | $0.00 | $0.00 | $0.00 |
| Operating cash flow | — | — | — |
| Free cash flow | — | — | — |
| Diluted shares | 69.5M | 63.0M | 43.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $606.2M | $150.1M | $278.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $2.2M | $100.1M | $61.3M |
| Total assets | $685.6M | $213.6M | $361.6M |
| Total liabilities | $151.5M | $171.3M | $144.9M |
| Shareholders' equity | $534.1M | $42.2M | $216.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology